AMG National Trust Bank Purchases 4,073 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

AMG National Trust Bank grew its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 3.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 133,738 shares of the company’s stock after acquiring an additional 4,073 shares during the period. AMG National Trust Bank’s holdings in Elanco Animal Health were worth $1,965,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ELAN. Benjamin F. Edwards & Company Inc. raised its position in Elanco Animal Health by 337.7% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after purchasing an additional 1,361 shares during the last quarter. ORG Wealth Partners LLC purchased a new position in shares of Elanco Animal Health during the third quarter valued at approximately $29,000. ORG Partners LLC bought a new position in shares of Elanco Animal Health during the second quarter valued at approximately $31,000. nVerses Capital LLC purchased a new stake in Elanco Animal Health in the second quarter worth $32,000. Finally, AM Squared Ltd bought a new stake in Elanco Animal Health in the third quarter valued at $34,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Elanco Animal Health news, Director Michael J. Harrington acquired 3,500 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were acquired at an average cost of $14.85 per share, with a total value of $51,975.00. Following the transaction, the director now owns 81,094 shares of the company’s stock, valued at $1,204,245.90. The trade was a 4.51 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.57% of the stock is currently owned by company insiders.

Elanco Animal Health Price Performance

Shares of ELAN opened at $13.45 on Tuesday. The firm’s 50-day simple moving average is $13.79 and its two-hundred day simple moving average is $14.77. Elanco Animal Health Incorporated has a fifty-two week low of $11.40 and a fifty-two week high of $18.80. The stock has a market cap of $6.65 billion, a PE ratio of 33.63, a price-to-earnings-growth ratio of 1.46 and a beta of 1.41. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the company earned $0.18 EPS. The firm’s revenue for the quarter was down 3.6% on a year-over-year basis. Analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on ELAN. Morgan Stanley lowered shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $17.00 to $15.00 in a report on Thursday, September 19th. Stifel Nicolaus reissued a “buy” rating and issued a $20.00 price target on shares of Elanco Animal Health in a research note on Thursday, September 19th. Finally, Barclays lifted their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $17.14.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.